Mumps outbreak in Keralam: Why MMR vaccine inclusion in UIP is critical

18 Oct Mumps outbreak in Keralam: Why MMR vaccine inclusion in UIP is critical

✎ The MMR vaccine, though available in the private sector, is excluded from India’s Universal Immunisation Programme, leaving a critical gap in mumps prevention; the NTAGI’s cost-effectiveness rationale contrasts with evidence of…

Subject Relevance — Where This Topic Fits

• GS Paper II — Governance, Constitution and Polity (Public Health Governance)  |  GS Paper III — Science and Technology (Health Research and Development, Vaccine Policy)
• Prelims: Mumps, MMR vaccine, Universal Immunisation Programme (UIP), National Technical Advisory Group on Immunisation (NTAGI), Immunity gaps, Measles-Rubella (MR) vaccine, Paediatric immunisation schedule, Vaccine-preventable diseases, Kerala Health Department, NTAGI recommendations
• Essay: The interplay between public health policy and scientific evidence in disease prevention, Ethical considerations in prioritising vaccine inclusion in national immunisation programmes

Quick Revision: The MMR vaccine, though available in the private sector, is excluded from India’s Universal Immunisation Programme, leaving a critical gap in mumps prevention; the NTAGI’s cost-effectiveness rationale contrasts with evidence of immunity gaps and complications, necessitating a re-evaluation of immunisation policy priorities.

Why is this in the news?

The continuing mumps outbreak in Keralam, persisting since late 2023 and affecting over 100,000 individuals by 2026, has reignited debates on the exclusion of the mumps component from India’s Universal Immunisation Programme (UIP). The outbreak, marked by school closures and documented complications including long-term disability, has highlighted immunity gaps among children and genetic mismatches between circulating mumps strains and vaccine strains. This has prompted renewed calls for the inclusion of the MMR vaccine in the UIP, raising questions about India’s immunisation policy priorities, vaccine efficacy, and public health surveillance mechanisms.

Background

• Mumps is a viral disease caused by the mumps virus, primarily affecting children and adolescents, characterised by swelling of the salivary glands, fever, and potential complications such as meningitis, encephalitis, orchitis, and long-term sequelae like hearing loss.
• The MMR vaccine, introduced in India in the 1980s, provides immunity against measles, mumps, and rubella, and has been recommended by the Indian Academy of Paediatrics (IAP) for routine immunisation since its inception.
• India’s Universal Immunisation Programme (UIP), launched in 1985, provides free vaccines against 12 vaccine-preventable diseases, including measles and rubella, but excludes mumps, relying instead on the MR vaccine.
• The National Technical Advisory Group on Immunisation (NTAGI), established in 2001, advises the Ministry of Health and Family Welfare on immunisation policy, including vaccine introduction and schedule modifications.
• Keralam has reported a significant surge in mumps cases since 2023, with 74,907 cases in 2024 and 26,462 in 2025, alongside documented outbreaks in other states, raising concerns about regional disparities in disease burden and immunisation coverage.
• The debate over MMR inclusion in the UIP centres on cost-effectiveness, disease burden documentation, vaccine efficacy against circulating strains, and the balance between public health priorities and resource allocation.

What is the MMR vaccine and its role in immunisation policy?

• The MMR vaccine is a live-attenuated vaccine that provides immunity against measles, mumps, and rubella, administered in two doses: the first at 12–15 months and the second at 4–6 years of age.
• The vaccine’s efficacy is high, with studies indicating over 95% protection against measles and rubella and approximately 88% protection against mumps after two doses, though effectiveness can wane over time.
• The MMR vaccine is included in the immunisation schedules of many countries, including the United States (CDC), the United Kingdom (NHS), and several European nations, as part of their national immunisation programmes.
• In India, the MMR vaccine is available in the private sector but is not part of the UIP, which instead provides the MR vaccine, leaving the mumps component unaddressed in the public health system.
• The exclusion of mumps from the UIP is justified by the NTAGI on grounds of cost-effectiveness, low mortality associated with mumps, and perceived limited public health impact, despite evidence of complications and long-term disability.
• The Indian Academy of Paediatrics (IAP) has consistently recommended the inclusion of the MMR vaccine in the UIP, citing the underestimation of mumps’ disease burden and the need for comprehensive immunisation.
• The debate over MMR inclusion also involves considerations of vaccine strain matching, as genetic differences between circulating mumps strains and the vaccine strain may reduce effectiveness, necessitating periodic reviews of vaccine formulations.
• Public health experts argue that the lack of systematic surveillance and documentation of mumps complications in India contributes to the policy inertia, underscoring the need for improved epidemiological data.

Key Features

Feature	Significance
Mumps transmission	Highly contagious viral disease spread via respiratory droplets, saliva, or contaminated surfaces, leading to prolonged outbreaks in densely populated settings such as schools and hostels.
MMR vaccine efficacy	Protects against measles, mumps, and rubella; mumps component addresses immunity gaps and reduces complications, including orchitis, meningitis, and long-term neurological sequelae.
UIP exclusion of MMR	Current UIP provides MR vaccine (measles-rubella) but excludes mumps component, leaving a critical gap in preventive coverage despite vaccine-preventable nature of the disease.
Immunity gaps in children	Documented waning immunity post-MR vaccination and genetic divergence between circulating mumps virus strains and vaccine strain reduce protective efficacy, necessitating MMR inclusion.
Public health surveillance	Inadequate systematic documentation of mumps complications and long-term outcomes in India obscures true disease burden, complicating evidence-based policy decisions.

Why it Matters

Public Health Impact

• Mumps outbreaks disrupt educational continuity, with repeated school closures in Keralam (Alappuzha, Thrissur, Kottayam) affecting over 26,000 cases in 2025 alone.
• Complications such as orchitis (testicular inflammation), aseptic meningitis, and sensorineural hearing loss impose lifelong disability burdens, particularly among adolescent males.
• Long-term neurological sequelae, including encephalitis, though rare, contribute to avoidable morbidity and healthcare costs.

Policy and Governance

• The NTAGI’s exclusion of mumps from UIP is based on cost-effectiveness analyses that underestimate non-fatal disease burden and disability-adjusted life years (DALYs).
• State-level demands (e.g., Tamil Nadu’s RTI response) highlight the need for harmonised national immunisation policies responsive to regional epidemiological trends.
• Private sector availability of MMR since the 1980s underscores inequities in access, as economically weaker sections rely solely on UIP-provided vaccines.

Economic Implications

• Direct healthcare costs from mumps complications (hospitalisations, outpatient care) strain public health budgets, particularly in states with recurrent outbreaks.
• Indirect costs include parental workdays lost due to childcare during outbreaks and school disruptions, disproportionately affecting low-income households.
• Cost-benefit analyses of MMR inclusion must account for avoided DALYs and productivity losses, not merely vaccine procurement expenses.

Scientific and Epidemiological

• Genetic drift in circulating mumps virus strains (genotype G) reduces cross-protection from existing MR vaccines, necessitating strain-specific booster strategies.
• Serological surveillance gaps obscure true immunity levels, delaying evidence-based adjustments to immunisation schedules.
• International precedents (e.g., WHO recommendations) advocate for MMR inclusion where mumps incidence exceeds 5 cases per 100,000 population, a threshold Keralam has repeatedly surpassed.

Challenges

1. Inadequate Disease Surveillance

• Mumps is not a notifiable disease under the Integrated Disease Surveillance Programme (IDSP), leading to underreporting and delayed outbreak responses.
• Lack of standardised protocols for documenting complications (e.g., orchitis, encephalitis) hampers policy prioritisation.

UPSC Link: GS-II: Health (IDSP, Surveillance Systems)

2. Cost-Effectiveness Dilemma

• NTAGI’s cost-benefit analysis prioritises mortality reduction, overlooking mumps-associated DALYs and long-term disability costs.
• Vaccine pricing disparities between MR and MMR (2–3x higher) create fiscal barriers despite potential savings from avoided complications.

UPSC Link: GS-II: Health (Vaccine Economics, UIP)

3. Vaccine Strain Mismatch

• The Jeryl Lynn strain in the MMR vaccine shows reduced efficacy against genotype G mumps virus, necessitating periodic vaccine strain updates.
• Delayed adaptation of vaccine strains to circulating genotypes risks sustained transmission despite high vaccination coverage.

UPSC Link: GS-III: Science & Tech (Vaccine Development)

4. Equity in Immunisation Access

• Private sector MMR availability exacerbates disparities, as economically disadvantaged populations lack access to paid vaccination.
• State-specific outbreaks (e.g., Keralam, Tamil Nadu) highlight the need for uniform national immunisation policies.

UPSC Link: GS-II: Health (Equity, UIP)

5. Public Health Communication Gaps

• Low awareness of mumps complications (e.g., infertility risks, neurological damage) among parents and healthcare providers undermines vaccine uptake.
• Misconceptions about mumps as a
• benign
• disease persist, delaying demand for preventive measures.

UPSC Link: GS-II: Health (Behavioural Change, IEC)

Challenges — UPSC Perspective

Issue	Concern
Surveillance gaps	Underreporting of mumps cases and complications due to non-notification status under IDSP.
Vaccine strain mismatch	Circulating genotype G mumps virus shows reduced susceptibility to Jeryl Lynn strain in MMR vaccine.
Cost-benefit misalignment	NTAGI’s analysis undervalues mumps-associated DALYs, skewing policy prioritisation.
Equity in access	Private sector MMR availability creates disparities in immunisation coverage.
Public awareness deficit	Low perception of mumps severity among parents and healthcare providers.
Policy inertia	Delayed adaptation of UIP to include MMR despite evidence of immunity gaps.

Way Forward

• Strengthen mumps surveillance by integrating it into the IDSP as a notifiable disease to improve real-time data collection and outbreak response.
• Conduct sero-epidemiological studies in high-incidence states (e.g., Keralam, Tamil Nadu) to quantify immunity gaps and guide booster strategies.
• Re-evaluate NTAGI’s cost-effectiveness criteria to incorporate DALYs and long-term disability costs associated with mumps complications.
• Update MMR vaccine strain to match circulating genotypes (e.g., genotype G) to enhance protective efficacy.
• Expand UIP to include MMR vaccine, prioritising phased rollout in states with recurrent outbreaks and high disease burden.
• Launch targeted public health campaigns to educate parents and healthcare providers on mumps complications and the benefits of MMR vaccination.
• Establish a national task force to review immunisation policies biennially, ensuring responsiveness to emerging epidemiological trends.
• Pilot school-based MMR catch-up campaigns in outbreak-prone districts to close immunity gaps among adolescents.

UPSC Value Addition

Prelims Practice Questions

Q1. Consider the following statements regarding the Universal Immunisation Programme (UIP) in India:
1. The UIP provides two doses of the measles-rubella (MR) vaccine.
2. The UIP includes the mumps component in its vaccination schedule.
3. The National Technical Advisory Group on Immunisation (NTAGI) is responsible for recommending vaccine inclusion in the UIP.
4. The UIP is a centrally sponsored scheme implemented by State governments.

How many of the above statements are correct?

1. Only one
2. Only two
3. Only three
4. All

Answer: Only three — Statements 1, 3, and 4 are correct. Statement 2 is incorrect as the UIP does not include the mumps component; it provides MR vaccine only.

Q2. Assertion (A): The Indian Academy of Paediatrics (IAP) has long recommended the inclusion of the MMR vaccine in place of the MR vaccine in the Universal Immunisation Programme (UIP).
Reason (R): The IAP argues that mumps imposes significant long-term disability and its burden is underestimated in public health policy.

Options:
A. Both A and R are true, and R is the correct explanation of A.
B. Both A and R are true, but R is not the correct explanation of A.
C. A is true, but R is false.
D. A is false, but R is true.

Answer: ? — Both the Assertion (A) and Reason (R) are true, and R correctly explains A, as the IAP’s recommendation is based on the underestimation of mumps’ public health burden.

Q3. Match the following columns regarding vaccine-preventable diseases and their inclusion in the Universal Immunisation Programme (UIP):

Column I (Disease)
1. Measles
2. Rubella
3. Mumps
4. Polio

Column II (Vaccine in UIP)
A. Included
B. Not included

Select the correct match:

1. 1-A, 2-A, 3-B, 4-A
2. 1-A, 2-A, 3-A, 4-B
3. 1-A, 2-B, 3-B, 4-A
4. 1-B, 2-A, 3-B, 4-A

Answer: 1-A, 2-A, 3-B, 4-A — Measles, Rubella, and Polio are included in the UIP (1-A, 2-A, 4-A), while Mumps is not included (3-B).

Mains Practice Question

✍ The exclusion of the mumps component from the Universal Immunisation Programme (UIP) has led to recurrent outbreaks in states like Kerala, despite the availability of the MMR vaccine. Critically examine the policy, institutional, and epidemiological factors underlying this exclusion. Also, assess the consequences of continuing this exclusion for public health in India. (15 Marks)

Approach: MODEL-ANSWER SKELETON:

1. **Policy Context and UIP Framework**:
– Define the UIP and its objectives (preventing vaccine-preventable diseases, reducing child mortality).
– List diseases covered under UIP (measles, rubella, polio, DPT, BCG, etc.) and explicitly exclude mumps.
– Mention the role of the National Technical Advisory Group on Immunisation (NTAGI) in vaccine inclusion decisions.

2. **Institutional and Decision-Making Processes**:
– Explain the criteria for vaccine inclusion in UIP: disease prevalence, mortality, vaccine efficacy, cost-effectiveness, and public health impact.
– Highlight the NTAGI’s stance on mumps: low mortality, limited documentation of long-term complications, and cost concerns (MR vs. MMR).
– Discuss the Indian Academy of Paediatrics (IAP) recommendation for MMR inclusion and its rationale (underestimation of mumps burden, genetic strain mismatch).

3. **Epidemiological and Surveillance Gaps**:
– Cite Kerala’s mumps outbreak data (74,907 cases in 2024, 26,462 in 2025) and its impact (school closures, long-term complications).
– Emphasise the lack of systematic surveillance and documentation of mumps complications in India.
– Explain the strain mismatch issue: circulating mumps virus vs. vaccine strain, leading to reduced vaccine efficacy.

4. **Consequences of Exclusion**:
– Short-term: Recurrent outbreaks, school closures, economic burden on families and healthcare systems.
– Long-term: Underestimation of disability-adjusted life years (DALYs) lost due to mumps complications (orchitis, meningitis, deafness).
– Systemic: Erosion of public trust in immunisation programmes, potential spillover to other vaccine-preventable diseases.

5. **Comparative Perspective**:
– Contrast India’s policy with global practices (e.g., WHO recommendations, inclusion of MMR in many national immunisation programmes).
– Highlight the cost-effectiveness debate: compare the incremental cost of MMR vs. MR and its impact on UIP budget.

6. **Way Forward**:
– Strengthen surveillance systems to document mumps burden and complications.
– Re-evaluate NTAGI’s criteria for mumps inclusion, considering emerging evidence.
– Pilot MMR inclusion in high-burden states as a phased approach.

Source: The Hindu

---

Generated by AanyaAi for educational purpose.

---

Related guides on our sites

• Best mentorship programme for upsc
• How to prepare for GS paper 1 for UPSC CSE mains exam
• Best UPSC coaching for IFOS exam
• UPSC+BA degree